Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (71-80 of 266) with videos related to

Pageof 27
Sort By:
Cell Systems|July 2, 2018
IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to ImmunotherapyJames C Chen, Rolando Perez-Lorenzo, Yvonne M Saenger, et al.
Cell Stem Cell|April 2, 2019
A Subset of TREM2<sup>+</sup> Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair GrowthEtienne C E Wang, Zhenpeng Dai, Anthony W Ferrante, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?Charlene M Fares, Eliezer M Van Allen, Charles G Drake, et al.
World Journal of Urology|October 22, 2015
Immune checkpoint inhibitors: a new frontier in bladder cancerMax Kates, Nikolai A Sopko, Hotaka Matsui, et al.
Plos Medicine|October 21, 2009
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical dataTakeshi Azuma, Gefeng Zhu, Haiying Xu, et al.
The Prostate|November 7, 2012
Strain-specific induction of experimental autoimmune prostatitis (EAP) in miceChristopher M Jackson, Dallas B Flies, Claudio A Mosse, et al.
Immunotargets and Therapy|April 1, 2017
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancerMark Scholz, Sabrina Yep, Micah Chancey, et al.
Biotechniques|July 13, 2016
A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cellsJelani C Zarif, James R Hernandez, James E Verdone, et al.
Journal of the National Cancer Institute|April 5, 2017
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentJames L Gulley, Ravi A Madan, Russell Pachynski, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector functionAmy D H Doody, Joseph T Kovalchin, Marianne A Mihalyo, et al.
Pageof 27

Showing results (71-80 of 266) with videos related to

Sort By:
Pageof 27
Cell Systems|July 2, 2018
IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to ImmunotherapyJames C Chen, Rolando Perez-Lorenzo, Yvonne M Saenger, et al.
Cell Stem Cell|April 2, 2019
A Subset of TREM2<sup>+</sup> Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair GrowthEtienne C E Wang, Zhenpeng Dai, Anthony W Ferrante, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?Charlene M Fares, Eliezer M Van Allen, Charles G Drake, et al.
World Journal of Urology|October 22, 2015
Immune checkpoint inhibitors: a new frontier in bladder cancerMax Kates, Nikolai A Sopko, Hotaka Matsui, et al.
Plos Medicine|October 21, 2009
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical dataTakeshi Azuma, Gefeng Zhu, Haiying Xu, et al.
The Prostate|November 7, 2012
Strain-specific induction of experimental autoimmune prostatitis (EAP) in miceChristopher M Jackson, Dallas B Flies, Claudio A Mosse, et al.
Immunotargets and Therapy|April 1, 2017
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancerMark Scholz, Sabrina Yep, Micah Chancey, et al.
Biotechniques|July 13, 2016
A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cellsJelani C Zarif, James R Hernandez, James E Verdone, et al.
Journal of the National Cancer Institute|April 5, 2017
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentJames L Gulley, Ravi A Madan, Russell Pachynski, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector functionAmy D H Doody, Joseph T Kovalchin, Marianne A Mihalyo, et al.
Pageof 27